Connolly K.R.; Thase M.E. (2016). «Vortioxetine: a New Treatment for Major Depressive Disorder». Expert Opinion on Pharmacotherapy17 (3): 421-431. PMID26679430. doi:10.1517/14656566.2016.1133588. «The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.»
Köhler S.; Cierpinsky K.; Kronenberg G.; Adli M. (2016). «The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.». J Psychopharmacol.30 (1): 13-22. PMID26464458. doi:10.1177/0269881115609072.
Pae C-U.; Wang S-M.; Han C.; Lee S-J.; Patkar AA.; Masand PS.; Serretti A. (2015). «Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis». Journal of Psychiatric Research64: 88-98. ISSN1879-1379. PMID25851751. doi:10.1016/j.jpsychires.2015.02.017.
Sanchez C.; Asin KE.; Artigas F. (2015). «Vortioxetine, a Novel Antidepressant with Multimodal Activity: Review of Preclinical and Clinical Data». Pharmacology & Therapeutics145: 43-57. ISSN1879-016X. PMID25016186. doi:10.1016/j.pharmthera.2014.07.001.
Bang-Andersen B.; Ruhland T.; Jørgensen M. (2011). «Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder». Journal of Medicinal Chemistry54 (9): 3206-3221. PMID21486038. doi:10.1021/jm101459g.
N. Moore; B. Bang-Andersen; L. Brennum; K. Fredriksen; S. Hogg; A. Mork; T. Stensbol; H. Zhong ; C. Sanchez ; D. Smith (2008). «Lu AA21004: a novel potential treatment for mood disorders». European Neuropsychopharmacology18 (Supplement 4): S321. doi:10.1016/S0924-977X(08)70440-1.
Pae C-U.; Wang S-M.; Han C.; Lee S-J.; Patkar AA.; Masand PS.; Serretti A. (2015). «Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis». Journal of Psychiatric Research64: 88-98. ISSN1879-1379. PMID25851751. doi:10.1016/j.jpsychires.2015.02.017.
Sanchez C.; Asin KE.; Artigas F. (2015). «Vortioxetine, a Novel Antidepressant with Multimodal Activity: Review of Preclinical and Clinical Data». Pharmacology & Therapeutics145: 43-57. ISSN1879-016X. PMID25016186. doi:10.1016/j.pharmthera.2014.07.001.
medicaid.gov
data.medicaid.gov
«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services(en inglés). Archivado desde el original el 6 de marzo de 2019. Consultado el 3 de marzo de 2019.
nih.gov
ncbi.nlm.nih.gov
Connolly K.R.; Thase M.E. (2016). «Vortioxetine: a New Treatment for Major Depressive Disorder». Expert Opinion on Pharmacotherapy17 (3): 421-431. PMID26679430. doi:10.1517/14656566.2016.1133588. «The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.»
Köhler S.; Cierpinsky K.; Kronenberg G.; Adli M. (2016). «The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.». J Psychopharmacol.30 (1): 13-22. PMID26464458. doi:10.1177/0269881115609072.
Pae C-U.; Wang S-M.; Han C.; Lee S-J.; Patkar AA.; Masand PS.; Serretti A. (2015). «Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis». Journal of Psychiatric Research64: 88-98. ISSN1879-1379. PMID25851751. doi:10.1016/j.jpsychires.2015.02.017.
Sanchez C.; Asin KE.; Artigas F. (2015). «Vortioxetine, a Novel Antidepressant with Multimodal Activity: Review of Preclinical and Clinical Data». Pharmacology & Therapeutics145: 43-57. ISSN1879-016X. PMID25016186. doi:10.1016/j.pharmthera.2014.07.001.
Bang-Andersen B.; Ruhland T.; Jørgensen M. (2011). «Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder». Journal of Medicinal Chemistry54 (9): 3206-3221. PMID21486038. doi:10.1021/jm101459g.
web.archive.org
«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services(en inglés). Archivado desde el original el 6 de marzo de 2019. Consultado el 3 de marzo de 2019.
